Advertisement

Treatment of High-Normal Blood Pressure in the Guidelines

  • Jana Brguljan
  • Giuseppe Ambrosio
Chapter
Part of the Updates in Hypertension and Cardiovascular Protection book series (UHCP)

Abstract

Considering treatment of high-normal blood pressure population means changing from a high-risk to a low-risk population strategy, affording greater population benefit. It is important to discover among this population masked hypertensive subjects, which may demand immediate pharmacological treatment, while the rest of the group should follow, according to present guidelines, lifestyle changes.

Keywords

High-normal blood pressure Prehypertension Guidelines Lifestyle changes 

References

  1. 1.
    Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–23.CrossRefPubMedGoogle Scholar
  2. 2.
    Lim SS, Vos T, Flaxman AD, Danaei G, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–60.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13.CrossRefGoogle Scholar
  4. 4.
    Whitworth JA, World Health Organization ISoHWG. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21(11):1983–92.CrossRefPubMedGoogle Scholar
  5. 5.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–52.CrossRefGoogle Scholar
  6. 6.
    James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland D, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint Committee (JNC 8). JAMA. 2014;311:507–20.CrossRefGoogle Scholar
  7. 7.
    Mainous AG III, Everett CJ, Liszka H, King DE, Egan BM. Prehypertension and mortality in a nationally representative cohort. Am J Cardiol. 2004;94:1496–500.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Liszka HA, Mainous AG III, King DE, Everett CJ, Egan BM. Prehypertension and cardiovascular morbidity. Ann Fam Med. 2005;3:294–9.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219.CrossRefGoogle Scholar
  10. 10.
    Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, Nerenberg K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallée M, Prasad GVR, Gryn SE, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Sivapalan P, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NRC, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Kline G, Leiter LA, Jones C, Côté AM, Woo V, Kaczorowski J, Trudeau L, Tsuyuki RT, Hiremath S, Drouin D, Lavoie KL, Hamet P, Grégoire JC, Lewanczuk R, Dresser GK, Sharma M, Reid D, Lear SA, Moullec G, Gupta M, Magee LA, Logan AG, Dionne J, Fournier A, Benoit G, Feber J, Poirier L, Padwal RS, Rabi DM. Hypertension Canada's 2017 Guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017;33(5):557–76.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B, Management of Arterial Hypertension of the European Society of Hypertension, European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: the task force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–87.CrossRefGoogle Scholar
  12. 12.
    Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C, et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009;27:1719–42.CrossRefPubMedGoogle Scholar
  13. 13.
    James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.CrossRefGoogle Scholar
  14. 14.
  15. 15.
    Terry PD, Abramson JL, Neaton JD, MRFIT Research Group. Blood pressure and risk of death from external causes among men screened for the multiple risk factor intervention trial. Am J Epidemiol. 2007;165(3):294–301.CrossRefPubMedGoogle Scholar
  16. 16.
    Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001;358(9294):1682–6.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Zhang H, Thijs L, Kuznetsova T, Fagard RH, Li X, Staessen JAJ. Progression to hypertension in the non-hypertensive participants in the Flemish Study on environment, genes and health outcomes. Hypertension. 2006;24(9):1719–27.CrossRefGoogle Scholar
  18. 18.
    Julius S, Majahalme S, Nesbitt S, Grant E, Kaciroti N, Ombao H, Vriz O, Valentini MC, Amerena J, Gleiberman L. A “gender blind” relationship of lean body mass and blood pressure in the Tecumseh study. Am J Hypertens. 2002;15(3):258–63.CrossRefPubMedGoogle Scholar
  19. 19.
    Xu T, Liu J, Zhu G, Liu J, Han S. Prevalence of prehypertension and associated risk factors among Chinese adults from a large-scale multi-ethnic population survey. BMC Public Health. 2016;16(1):775.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Pimenta E, Oparil S. Prehypertension: epidemiology, consequences and treatment. Nat Rev Nephrol. 2010;6(1):21–30.CrossRefPubMedGoogle Scholar
  21. 21.
    Julius S, Nesbitt SD, Egan BM, et al., Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685–97.CrossRefGoogle Scholar
  22. 22.
    Vasan RS, Larson MG, Leip EP, Evans JC, O’Donnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345(18):1291–7.CrossRefGoogle Scholar
  23. 23.
    Hansen TW, Staessen JA, Zhang H, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. Cardiovascular outcome in relation to progression to hypertension in the Copenhagen MONICA cohort. Am J Hypertens. 2007;20(5):483–91.CrossRefPubMedGoogle Scholar
  24. 24.
    Staessen JA, Li Y, Hara A, Asayama K, Dolan E, O’Brien E. Blood pressure measurement anno 2016. Am J Hypertens. 2017;30(5):453–63.PubMedGoogle Scholar
  25. 25.
    Celis H, Fagard RH. White-coat hypertension: a clinical review. Eur J Intern Med. 2004;15(6):348–57.CrossRefPubMedGoogle Scholar
  26. 26.
    Brguljan-Hitij J, Thijs L, Li Y, Hansen TW, Boggia J, Liu YP, Asayama K, Wei FF, Bjorklund-Bodegard K, Gu YM, Ohkubo T, Jeppesen J, Torp-Pedersen C, Dolan E, Kuznetsova T, Katarzyna SS, Tikhonoff V, Malyutina S, Casiglia E, Nikitin Y, Lind L, Sandoya E, Kawecka-Jaszcz K, Filipovsky J, Imai Y, Wang J, O’Brien E, Staessen JA, on behalf of the International Database on Ambulatory blood pressure in relation to Cardiovascular Outcome Investigators. Risk stratification by ambulatory blood pressure monitoring across JNC classes of conventional blood pressure. Am J Hypertens. 2014;27(7):956–65.CrossRefPubMedGoogle Scholar
  27. 27.
    Manios E, Michas F, Tsivgoulis G, Stamatelopoulos K, Tsagalis G, Koroboki E, Alexaki E, Papamichael C, Vemmos K, Zakopoulos N. Impact of prehypertension on carotid artery intima-media thickening: actual or masked? Atherosclerosis. 2011;214(1):215–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Shimbo D, Newman JD, Schwartz JE. Masked hypertension and prehypertension: diagnostic overlap and interrelationships with left ventricular mass: the Masked Hypertension Study. Am J Hypertens. 2012;25(6):664–71.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Lüders S, Schrader J, Berger J, et al. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure – a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008;26:1487–96.CrossRefGoogle Scholar
  30. 30.
    Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462–536.PubMedGoogle Scholar
  31. 31.
    Sever P, Dahlöf B, Poulter N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian cardiac outcomes trial. Eur Heart J. 2006;27:2982–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61:1086–97.CrossRefPubMedGoogle Scholar
  33. 33.
    Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet. 2000;355:253–9.CrossRefGoogle Scholar
  34. 34.
    ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–40.CrossRefGoogle Scholar
  35. 35.
    PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033–41.CrossRefGoogle Scholar
  36. 36.
    Arima H, Chalmers J, Woodward M, Anderson C, Rodgers A, Davis S, MacMahon S, Neal B, for the PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens. 2006;24:1201–8.CrossRefGoogle Scholar
  37. 37.
    PATS Collaborating Group. Poststroke antihypertensive treatment study. A preliminary result. Chin Med J. 1995;108:710–7.Google Scholar
  38. 38.
    Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical re-appraisal. J Hypertens. 2009;27:923–34.CrossRefPubMedGoogle Scholar
  39. 39.
    Aglony M, Acevedo M, Ambrosio G. Hypertension in adolescents. Expert Rev Cardiovasc Ther. 2009;7(12):1595–603.CrossRefPubMedGoogle Scholar
  40. 40.
    Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42:878–84.CrossRefPubMedGoogle Scholar
  41. 41.
    Horvath K, Jeitler K, Siering U, Stich AK, Skipka G, Gratzer TW, Siebenhofer A. Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis. Arch Intern Med. 2008;168(6):571–80.CrossRefPubMedGoogle Scholar
  42. 42.
    Siebenhofer A, Jeitler K, Berghold A, Waltering A, Hemkens LG, Semlitsch T, Pachler C, Strametz R, Horvath K. Long-term effects of weight-reducing diets in hypertensive patients. Cochrane Database Syst Rev. 2011;9:CD008274.Google Scholar
  43. 43.
    Cornelissen VA, Fagard RH. Effects of endurance training on blood pressure, blood pressure-regulating mechanisms, and cardiovascular risk factors. Hypertension. 2005;46:667–75.CrossRefPubMedGoogle Scholar
  44. 44.
    Molmen-Hansen HE, Stolen T, Tjonna AE, Aamot IL, Ekeberg IS, Tyldum GA, et al. Aerobic interval training reduces blood pressure and improves myocardial function in hypertensive patients. Eur J Prev Cardiol. 2012;19:151–60.CrossRefPubMedGoogle Scholar
  45. 45.
    Cornelissen VA, Fagard RH, Coeckelberghs E, Vanhees L. Impact of resistance training on blood pressure and other cardiovascular risk factors: a meta-analysis of randomized, controlled trials. Hypertension. 2011;58:950–8.CrossRefGoogle Scholar
  46. 46.
    Fagard RH. Exercise therapy in hypertensive cardiovascular disease. Prog Cardiovasc Dis. 2011;53:404–11.CrossRefPubMedGoogle Scholar
  47. 47.
    He FJ, McGregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. J Hum Hypertens. 2002;16:761–70.CrossRefPubMedGoogle Scholar
  48. 48.
    van Mierlo LA, Arends LR, Streppel MT, Zeegers MP, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to calcium supplementation: a meta-analysis of randomized controlled trials. J Hum Hypertens. 2006;20(8):571–80.CrossRefPubMedGoogle Scholar
  49. 49.
    Jee SH, Miller ER 3rd, Guallar E, Singh VK, Appel LJ, Klag MJ. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. Am J Hypertens. 2002;15(8):691–6.CrossRefPubMedGoogle Scholar
  50. 50.
    Egan BM, Nesbitt SD, Julius S. Prehypertension: should we be treating with pharmacologic therapy? Ther Adv Cardiovasc Dis. 2008;2(4):305–14.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Hypertension, Internal DepartmentUniversity Medical Center LjubljanaLjubljanaSlovenia
  2. 2.Division of CardiologyUniversity of Perugia School of MedicinePerugiaItaly

Personalised recommendations